Latest Market News

Page 331 of 1983
NEXTDC has reported a robust first half of FY26, with strong revenue and earnings growth underpinned by a surging forward order book and expanded capital expenditure plans.
Sophie Babbage
Sophie Babbage
25 Feb 2026
betr Entertainment has extended its NAB facility agreement maturity to July 2027, reinforcing its financial flexibility and growth ambitions. This move underscores a strong partnership with NAB amid betr’s evolving wagering business.
Claire Turing
Claire Turing
25 Feb 2026
State Street SPDR Core Equity ETFs have reported consistent half-year results for the period ending 31 December 2025, maintaining alignment with their benchmark indices and continuing to provide reliable distributions to unitholders.
Claire Turing
Claire Turing
25 Feb 2026
Cyclopharm Limited reported a 17% revenue increase to a record $32.3 million in 2025, powered by a 226% surge in US Technegas sales. The company is accelerating its US rollout with plans for up to 300 installations in 2026, while advancing clinical trials beyond pulmonary embolism.
Ada Torres
Ada Torres
25 Feb 2026
TPC Consolidated Limited reported a 4.1% revenue increase to $103.6 million and a 62% jump in underlying EBITDA for the half-year ended December 2025, while the proposed acquisition scheme faces regulatory hurdles.
Maxwell Dee
Maxwell Dee
25 Feb 2026
Piche Resources announces the resignation of Managing Director Karilyn Farmer effective April 2026, with seasoned geologist Claudio Devaux appointed as country manager to ensure continuity in exploration activities.
Maxwell Dee
Maxwell Dee
25 Feb 2026
EcoGraf Limited has completed a comprehensive update to its Bankable Feasibility Study for the Epanko Graphite Project, confirming robust financials and a production increase to 73,000 tonnes per annum. The study underpins advanced project financing and highlights significant expansion potential amid rising global graphite demand.
Maxwell Dee
Maxwell Dee
25 Feb 2026
Cleo Diagnostics reported a 53% drop in revenues and a slight increase in net loss to $1.98 million for H1 2025, while progressing its pivotal FDA clinical trial for an ovarian cancer blood test with strong regulatory and commercial milestones.
Ada Torres
Ada Torres
25 Feb 2026
Island Pharmaceuticals reports a 213.8% increase in half-year loss to $4.81 million, driven by strategic acquisition and clinical development investments. The company advances its antiviral portfolio with Galidesivir and ISLA-101, supported by strong US regulatory engagement and a $9 million capital raise.
Ada Torres
Ada Torres
25 Feb 2026
DUG Technology’s US subsidiary has been ordered to pay over US$2 million following a breach of contract ruling, but the company is gearing up to contest the judgment through appeals.
Sophie Babbage
Sophie Babbage
25 Feb 2026
Immuron Limited reported a narrower half-year loss alongside record sales growth and FDA approval for its IMM-529 drug candidate, signalling promising clinical and commercial momentum.
Ada Torres
Ada Torres
25 Feb 2026
Global Health Limited reports a modest half-year loss reduction alongside a steady rise in recurring SaaS revenue, signaling progress in its digital healthcare transformation.
Sophie Babbage
Sophie Babbage
25 Feb 2026